The Glycolytic Phenotype is Correlated with Aggressiveness and Poor Prognosis in Invasive Ductal Carcinomas
Glucose uptake and glycolytic metabolism are enhanced in cancer cells, and increased expression of glucose transporter 1 (GLUT1) has also been reported. The aim of this study was to investigate GLUT1 expression in human breast tissues and invasive ductal carcinomas. We used tissue microarrays consis...
Saved in:
Published in | Journal of breast cancer Vol. 15; no. 2; pp. 172 - 180 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Korea (South)
Korean Breast Cancer Society
01.06.2012
한국유방암학회 |
Subjects | |
Online Access | Get full text |
ISSN | 1738-6756 2092-9900 2092-9900 |
DOI | 10.4048/jbc.2012.15.2.172 |
Cover
Abstract | Glucose uptake and glycolytic metabolism are enhanced in cancer cells, and increased expression of glucose transporter 1 (GLUT1) has also been reported. The aim of this study was to investigate GLUT1 expression in human breast tissues and invasive ductal carcinomas.
We used tissue microarrays consisting of normal breast tissue, ductal hyperplasia, ductal carcinoma in situ, invasive ductal carcinoma, and lymph node metastases. We examined GLUT1 expression in the microarrays by immunohistochemistry, reviewed the medical records and performed a clinicopathological analysis.
Membranous GLUT1 expression was observed in normal and tumor cells. GLUT1 expression was higher in ductal carcinoma in situ, invasive ductal carcinoma, and lymph node metastasis than in normal tissue and ductal hyperplasia (p=0.002). Of 276 invasive ductal carcinomas, 106 (38.4%) showed GLUT1 expression. GLUT1 expression was correlated with higher histologic grade (p<0.001), larger tumor size (p=0.025), absence of estrogen receptor (p<0.001), absence of progesterone receptor (p<0.001), and triple-negative phenotype (p<0.001). In univariate survival analysis, patients with GLUT1 expression had poorer overall survival and disease-free survival (p=0.017 and p=0.021, respectively, log-rank test). In multivariate survival analysis with the Cox proportional hazards model, GLUT1 expression was an independent prognostic factor of poorer overall survival and disease-free survival (p=0.017 and p=0.019, respectively).
GLUT1 expression seems to play an important role in malignant transformation, and the glycolytic phenotype in invasive ductal carcinoma may indicate aggressive biological behavior and a worse prognosis. |
---|---|
AbstractList | Glucose uptake and glycolytic metabolism are enhanced in cancer cells, and increased expression of glucose transporter 1 (GLUT1) has also been reported. The aim of this study was to investigate GLUT1 expression in human breast tissues and invasive ductal carcinomas.PURPOSEGlucose uptake and glycolytic metabolism are enhanced in cancer cells, and increased expression of glucose transporter 1 (GLUT1) has also been reported. The aim of this study was to investigate GLUT1 expression in human breast tissues and invasive ductal carcinomas.We used tissue microarrays consisting of normal breast tissue, ductal hyperplasia, ductal carcinoma in situ, invasive ductal carcinoma, and lymph node metastases. We examined GLUT1 expression in the microarrays by immunohistochemistry, reviewed the medical records and performed a clinicopathological analysis.METHODSWe used tissue microarrays consisting of normal breast tissue, ductal hyperplasia, ductal carcinoma in situ, invasive ductal carcinoma, and lymph node metastases. We examined GLUT1 expression in the microarrays by immunohistochemistry, reviewed the medical records and performed a clinicopathological analysis.Membranous GLUT1 expression was observed in normal and tumor cells. GLUT1 expression was higher in ductal carcinoma in situ, invasive ductal carcinoma, and lymph node metastasis than in normal tissue and ductal hyperplasia (p=0.002). Of 276 invasive ductal carcinomas, 106 (38.4%) showed GLUT1 expression. GLUT1 expression was correlated with higher histologic grade (p<0.001), larger tumor size (p=0.025), absence of estrogen receptor (p<0.001), absence of progesterone receptor (p<0.001), and triple-negative phenotype (p<0.001). In univariate survival analysis, patients with GLUT1 expression had poorer overall survival and disease-free survival (p=0.017 and p=0.021, respectively, log-rank test). In multivariate survival analysis with the Cox proportional hazards model, GLUT1 expression was an independent prognostic factor of poorer overall survival and disease-free survival (p=0.017 and p=0.019, respectively).RESULTSMembranous GLUT1 expression was observed in normal and tumor cells. GLUT1 expression was higher in ductal carcinoma in situ, invasive ductal carcinoma, and lymph node metastasis than in normal tissue and ductal hyperplasia (p=0.002). Of 276 invasive ductal carcinomas, 106 (38.4%) showed GLUT1 expression. GLUT1 expression was correlated with higher histologic grade (p<0.001), larger tumor size (p=0.025), absence of estrogen receptor (p<0.001), absence of progesterone receptor (p<0.001), and triple-negative phenotype (p<0.001). In univariate survival analysis, patients with GLUT1 expression had poorer overall survival and disease-free survival (p=0.017 and p=0.021, respectively, log-rank test). In multivariate survival analysis with the Cox proportional hazards model, GLUT1 expression was an independent prognostic factor of poorer overall survival and disease-free survival (p=0.017 and p=0.019, respectively).GLUT1 expression seems to play an important role in malignant transformation, and the glycolytic phenotype in invasive ductal carcinoma may indicate aggressive biological behavior and a worse prognosis.CONCLUSIONGLUT1 expression seems to play an important role in malignant transformation, and the glycolytic phenotype in invasive ductal carcinoma may indicate aggressive biological behavior and a worse prognosis. Glucose uptake and glycolytic metabolism are enhanced in cancer cells, and increased expression of glucose transporter 1 (GLUT1) has also been reported. The aim of this study was to investigate GLUT1 expression in human breast tissues and invasive ductal carcinomas. We used tissue microarrays consisting of normal breast tissue, ductal hyperplasia, ductal carcinoma in situ, invasive ductal carcinoma, and lymph node metastases. We examined GLUT1 expression in the microarrays by immunohistochemistry, reviewed the medical records and performed a clinicopathological analysis. Membranous GLUT1 expression was observed in normal and tumor cells. GLUT1 expression was higher in ductal carcinoma in situ, invasive ductal carcinoma, and lymph node metastasis than in normal tissue and ductal hyperplasia (p=0.002). Of 276 invasive ductal carcinomas, 106 (38.4%) showed GLUT1 expression. GLUT1 expression was correlated with higher histologic grade (p<0.001), larger tumor size (p=0.025), absence of estrogen receptor (p<0.001), absence of progesterone receptor (p<0.001), and triple-negative phenotype (p<0.001). In univariate survival analysis, patients with GLUT1 expression had poorer overall survival and disease-free survival (p=0.017 and p=0.021, respectively, log-rank test). In multivariate survival analysis with the Cox proportional hazards model, GLUT1 expression was an independent prognostic factor of poorer overall survival and disease-free survival (p=0.017 and p=0.019, respectively). GLUT1 expression seems to play an important role in malignant transformation, and the glycolytic phenotype in invasive ductal carcinoma may indicate aggressive biological behavior and a worse prognosis. Purpose: Glucose uptake and glycolytic metabolism are enhanced in cancer cells, and increased expression of glucose transporter 1 (GLUT1) has also been reported. The aim of this study was to investigate GLUT1 expression in human breast tissues and invasive ductal carcinomas. Methods: We used tissue microarrays consisting of normal breast tissue, ductal hyperplasia, ductal carcinoma in situ, invasive ductal carcinoma, and lymph node metastases. We examined GLUT1 expression in the microarrays by immunohistochemistry, reviewed the medical records and performed a clinicopathological analysis. Results: Membranous GLUT1 expression was observed in normal and tumor cells. GLUT1 expression was higher in ductal carcinoma in situ, invasive ductal carcinoma, and lymph node metastasis than in normal tissue and ductal hyperplasia (p=0.002). Of 276 invasive ductal carcinomas, 106 (38.4%) showed GLUT1 expression. GLUT1 expression was correlated with higher histologic grade (p<0.001), larger tumor size (p=0.025), absence of estrogen receptor (p<0.001), absence of progesterone receptor (p<0.001), and triple-negative phenotype (p<0.001). In univariate survival analysis, patients with GLUT1 expression had poorer overall survival and disease-free survival (p=0.017 and p=0.021, respectively, log-rank test). In multivariate survival analysis with the Cox proportional hazards model, GLUT1 expression was an independent prognostic factor of poorer overall survival and disease-free survival (p=0.017 and p=0.019, respectively). Conclusion: GLUT1 expression seems to play an important role in malignant transformation, and the glycolytic phenotype in invasive ductal carcinoma may indicate aggressive biological behavior and a worse prognosis. KCI Citation Count: 19 |
Author | Chung, Min Sung Paik, Seung Sam Jang, Ki-Seok Min, Kyueng-Whan Jang, Si-Hyong Jun, Young Jin Han, Hulin Jang, Se Min |
AuthorAffiliation | 1 Department of Surgery, Hanyang University College of Medicine, Seoul, Korea Department of Pathology, Hanyang University College of Medicine, Seoul, Korea |
AuthorAffiliation_xml | – name: Department of Pathology, Hanyang University College of Medicine, Seoul, Korea – name: 1 Department of Surgery, Hanyang University College of Medicine, Seoul, Korea |
Author_xml | – sequence: 1 givenname: Se Min surname: Jang fullname: Jang, Se Min organization: Department of Pathology, Hanyang University College of Medicine, Seoul, Korea – sequence: 2 givenname: Hulin surname: Han fullname: Han, Hulin organization: Department of Pathology, Hanyang University College of Medicine, Seoul, Korea – sequence: 3 givenname: Ki-Seok surname: Jang fullname: Jang, Ki-Seok organization: Department of Pathology, Hanyang University College of Medicine, Seoul, Korea – sequence: 4 givenname: Young Jin surname: Jun fullname: Jun, Young Jin organization: Department of Pathology, Hanyang University College of Medicine, Seoul, Korea – sequence: 5 givenname: Si-Hyong surname: Jang fullname: Jang, Si-Hyong organization: Department of Pathology, Hanyang University College of Medicine, Seoul, Korea – sequence: 6 givenname: Kyueng-Whan surname: Min fullname: Min, Kyueng-Whan organization: Department of Pathology, Hanyang University College of Medicine, Seoul, Korea – sequence: 7 givenname: Min Sung surname: Chung fullname: Chung, Min Sung organization: Department of Surgery, Hanyang University College of Medicine, Seoul, Korea – sequence: 8 givenname: Seung Sam surname: Paik fullname: Paik, Seung Sam organization: Department of Pathology, Hanyang University College of Medicine, Seoul, Korea |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/22807934$$D View this record in MEDLINE/PubMed https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART001671102$$DAccess content in National Research Foundation of Korea (NRF) |
BookMark | eNp9kUFvEzEQhS1URNPCD-CCfOSSYHvt9fqCFKXQRqpEhMLZcryziZuNHWwnKP8eb0OrwgFZmjn4e--N9K7QhQ8eEHpPyYQT3nx6WNkJI5RNqJiUIdkrNGJEsbFShFygEZVVM66lqC_RVUoPhNS8kvINumSsIVJVfIS2yw3g2_5kQ3_KzuLFBnzIpz1gl_AsxAi9ydDiXy5v8HS9jpCSO4IvCxvf4kUIES9iWPuQisJ5PPdHMyD45mCz6fHMROt82Jn0Fr3uTJ_g3Z99jX58_bKc3Y3vv93OZ9P7seUVy2PTCkqhsdwy0SnacSOVUY1YEWsEIQKUrZq6vFaplnUdGCla0QjKO6AcSHWNPp59fez01jodjHvc66C3UU-_L-eaq7ohdUE_n9H9YbWD1oLP0fR6H93OxNOj8O8f7zbF5qirSgnJX2TtY_h5gJT1ziULfW88hEPSlDBJOKsJK-iHl1nPIU9lFICeARtDShG6Z4QSPRSuS-F6KFxTocuQg6n8R2NdNtmF4VzX_0f5GyStsj4 |
CitedBy_id | crossref_primary_10_18632_oncotarget_4499 crossref_primary_10_1096_fj_202001415RR crossref_primary_10_1007_s10911_013_9310_8 crossref_primary_10_1016_S0254_6272_17_30050_X crossref_primary_10_1038_ncomms8882 crossref_primary_10_1097_MD_0000000000012961 crossref_primary_10_1016_j_biopha_2023_114435 crossref_primary_10_1016_j_leukres_2015_12_008 crossref_primary_10_1038_s41598_018_27303_6 crossref_primary_10_1111_cas_12240 crossref_primary_10_1159_000358365 crossref_primary_10_1007_s12010_023_04373_5 crossref_primary_10_3390_cancers14020437 crossref_primary_10_3389_fonc_2023_1094480 crossref_primary_10_1002_mc_22988 crossref_primary_10_1007_s00432_019_02847_w crossref_primary_10_18632_oncotarget_17445 crossref_primary_10_1186_1471_2407_13_538 crossref_primary_10_4048_jbc_2015_18_1_1 crossref_primary_10_1186_s40644_020_00362_7 crossref_primary_10_1590_1806_9282_20221334 |
Cites_doi | 10.1016/j.pharmthera.2008.09.005 10.1128/MCB.23.20.7315-7328.2003 10.1073/pnas.93.5.1847 10.1016/j.gde.2006.12.006 10.1111/j.1349-7006.2002.tb01214.x 10.1016/S0959-8049(00)00371-3 10.4048/jkbcs.2001.4.2.167 10.1016/j.humpath.2009.09.001 10.1590/S1807-59322011000600008 10.1007/s00432-009-0652-y 10.1126/science.123.3191.309 10.1038/nrc1478 10.5858/2007-131-18-ASOCCO 10.1016/0898-6568(93)90028-K 10.5858/134.6.907 10.3322/canjclin.56.1.37 10.1371/journal.pone.0023205 10.1074/jbc.M010144200 10.1007/s00428-010-0938-0 10.1002/1097-0142(19931115)72:10<2979::AID-CNCR2820721020>3.0.CO;2-X 10.1016/j.semcancer.2008.11.009 10.1016/S1607-551X(09)70320-1 10.1002/ijc.2910560503 10.4048/jkbcs.2001.4.2.161 10.1016/S0022-5347(01)67725-5 |
ContentType | Journal Article |
Copyright | 2012 Korean Breast Cancer Society. All rights reserved. 2012 |
Copyright_xml | – notice: 2012 Korean Breast Cancer Society. All rights reserved. 2012 |
DBID | AAYXX CITATION NPM 7X8 5PM ACYCR |
DOI | 10.4048/jbc.2012.15.2.172 |
DatabaseName | CrossRef PubMed MEDLINE - Academic PubMed Central (Full Participant titles) Korean Citation Index |
DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic PubMed |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 2092-9900 |
EndPage | 180 |
ExternalDocumentID | oai_kci_go_kr_ARTI_496806 PMC3395740 22807934 10_4048_jbc_2012_15_2_172 |
Genre | Journal Article |
GroupedDBID | --- 5-W 5GY 8JR 8XY 9ZL AAYXX ADBBV ADRAZ AENEX ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL CITATION DIK DU5 EF. GROUPED_DOAJ HYE KQ8 M48 O5R O5S PGMZT RPM NPM 7X8 5PM ACYCR |
ID | FETCH-LOGICAL-c432t-ad511e8c4c25f91f4a79a985b0ca5005e9c386868d99d2ffea75d58514fe14e03 |
IEDL.DBID | M48 |
ISSN | 1738-6756 2092-9900 |
IngestDate | Tue Nov 21 21:30:10 EST 2023 Thu Aug 21 14:01:44 EDT 2025 Fri Jul 11 08:52:08 EDT 2025 Thu Jan 02 22:10:13 EST 2025 Tue Jul 01 01:56:40 EDT 2025 Thu Apr 24 23:00:46 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 2 |
Keywords | Breast Glucose transporter 1 Invasive ductal carcinoma Prognosis |
Language | English |
License | This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c432t-ad511e8c4c25f91f4a79a985b0ca5005e9c386868d99d2ffea75d58514fe14e03 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 These authors contributed equally to this work. G704-SER000010237.2012.15.2.012 |
OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.4048/jbc.2012.15.2.172 |
PMID | 22807934 |
PQID | 1027042602 |
PQPubID | 23479 |
PageCount | 9 |
ParticipantIDs | nrf_kci_oai_kci_go_kr_ARTI_496806 pubmedcentral_primary_oai_pubmedcentral_nih_gov_3395740 proquest_miscellaneous_1027042602 pubmed_primary_22807934 crossref_primary_10_4048_jbc_2012_15_2_172 crossref_citationtrail_10_4048_jbc_2012_15_2_172 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2012-06-01 |
PublicationDateYYYYMMDD | 2012-06-01 |
PublicationDate_xml | – month: 06 year: 2012 text: 2012-06-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | Korea (South) |
PublicationPlace_xml | – name: Korea (South) |
PublicationTitle | Journal of breast cancer |
PublicationTitleAlternate | J Breast Cancer |
PublicationYear | 2012 |
Publisher | Korean Breast Cancer Society 한국유방암학회 |
Publisher_xml | – name: Korean Breast Cancer Society – name: 한국유방암학회 |
References | Rathmell (10.4048/jbc.2012.15.2.172_ref4) 2003; 23 Gatenby (10.4048/jbc.2012.15.2.172_ref19) 2004; 4 Brown (10.4048/jbc.2012.15.2.172_ref14) 1993; 72 Ravazoula (10.4048/jbc.2012.15.2.172_ref26) 2003; 24 Ganapathy (10.4048/jbc.2012.15.2.172_ref20) 2009; 121 Young (10.4048/jbc.2012.15.2.172_ref5) 2011; 6 Zamora-León (10.4048/jbc.2012.15.2.172_ref21) 1996; 93 Semenza (10.4048/jbc.2012.15.2.172_ref7) 2009; 19 Merrall (10.4048/jbc.2012.15.2.172_ref17) 1993; 5 Warburg (10.4048/jbc.2012.15.2.172_ref3) 1956; 123 Schmidt (10.4048/jbc.2012.15.2.172_ref1) 2010; 136 Sakashita (10.4048/jbc.2012.15.2.172_ref11) 2001; 37 Chen (10.4048/jbc.2012.15.2.172_ref6) 2001; 276 Kuo (10.4048/jbc.2012.15.2.172_ref29) 2006; 22 Hammond (10.4048/jbc.2012.15.2.172_ref12) 2010; 134 Pinheiro (10.4048/jbc.2012.15.2.172_ref25) 2011; 26 Wolff (10.4048/jbc.2012.15.2.172_ref13) 2007; 131 Singletary (10.4048/jbc.2012.15.2.172_ref2) 2006; 56 Kim (10.4048/jbc.2012.15.2.172_ref27) 2001; 4 Carvalho (10.4048/jbc.2012.15.2.172_ref9) 2011; 66 Younes (10.4048/jbc.2012.15.2.172_ref30) 1995; 15 Gordan (10.4048/jbc.2012.15.2.172_ref8) 2007; 17 Mellanen (10.4048/jbc.2012.15.2.172_ref15) 1994; 56 Kang (10.4048/jbc.2012.15.2.172_ref24) 2002; 93 Nagase (10.4048/jbc.2012.15.2.172_ref16) 1995; 153 Clavo (10.4048/jbc.2012.15.2.172_ref18) 1995; 36 Chen (10.4048/jbc.2012.15.2.172_ref22) 2010; 457 Park (10.4048/jbc.2012.15.2.172_ref10) 2010; 41 Ahn (10.4048/jbc.2012.15.2.172_ref28) 2001; 4 Hao (10.4048/jbc.2012.15.2.172_ref23) 2009; 40 11166147 - Eur J Cancer. 2001 Jan;37(2):204-9 19655166 - J Cancer Res Clin Oncol. 2010 Feb;136(2):219-25 19292042 - Sichuan Da Xue Xue Bao Yi Xue Ban. 2009 Jan;40(1):44-7 21870331 - Histol Histopathol. 2011 Oct;26(10):1279-86 8221565 - Cancer. 1993 Nov 15;72(10):2979-85 20524868 - Arch Pathol Lab Med. 2010 Jun;134(6):907-22 20526721 - Virchows Arch. 2010 Jul;457(1):53-61 18992769 - Pharmacol Ther. 2009 Jan;121(1):29-40 8700847 - Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):1847-52 15516961 - Nat Rev Cancer. 2004 Nov;4(11):891-9 7658223 - J Nucl Med. 1995 Sep;36(9):1625-32 21808860 - Clinics (Sao Paulo). 2011;66(6):965-72 19114105 - Semin Cancer Biol. 2009 Feb;19(1):12-6 8314336 - Int J Cancer. 1994 Mar 1;56(5):622-9 13298683 - Science. 1956 Feb 24;123(3191):309-14 14658600 - Eur J Gynaecol Oncol. 2003;24(6):544-6 11120745 - J Biol Chem. 2001 Mar 23;276(12):9519-25 17208433 - Curr Opin Genet Dev. 2007 Feb;17(1):71-7 21826239 - PLoS One. 2011;6(8):e23205 12417042 - Jpn J Cancer Res. 2002 Oct;93(10):1123-8 19548375 - Arch Pathol Lab Med. 2007;131(1):18-43 16849102 - Kaohsiung J Med Sci. 2006 Jul;22(7):339-45 8130071 - Cell Signal. 1993 Nov;5(6):667-75 16449185 - CA Cancer J Clin. 2006 Jan-Feb;56(1):37-47; quiz 50-1 7861542 - J Urol. 1995 Mar;153(3 Pt 1):798-801 14517300 - Mol Cell Biol. 2003 Oct;23(20):7315-28 19954817 - Hum Pathol. 2010 Mar;41(3):431-7 8669885 - Anticancer Res. 1995 Nov-Dec;15(6B):2895-8 |
References_xml | – volume: 121 start-page: 29 year: 2009 ident: 10.4048/jbc.2012.15.2.172_ref20 publication-title: Pharmacol Ther doi: 10.1016/j.pharmthera.2008.09.005 – volume: 23 start-page: 7315 year: 2003 ident: 10.4048/jbc.2012.15.2.172_ref4 publication-title: Mol Cell Biol doi: 10.1128/MCB.23.20.7315-7328.2003 – volume: 93 start-page: 1847 year: 1996 ident: 10.4048/jbc.2012.15.2.172_ref21 publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.93.5.1847 – volume: 17 start-page: 71 year: 2007 ident: 10.4048/jbc.2012.15.2.172_ref8 publication-title: Curr Opin Genet Dev doi: 10.1016/j.gde.2006.12.006 – volume: 93 start-page: 1123 year: 2002 ident: 10.4048/jbc.2012.15.2.172_ref24 publication-title: Jpn J Cancer Res doi: 10.1111/j.1349-7006.2002.tb01214.x – volume: 37 start-page: 204 year: 2001 ident: 10.4048/jbc.2012.15.2.172_ref11 publication-title: Eur J Cancer doi: 10.1016/S0959-8049(00)00371-3 – volume: 4 start-page: 167 year: 2001 ident: 10.4048/jbc.2012.15.2.172_ref28 publication-title: J Korean Breast Cancer Soc doi: 10.4048/jkbcs.2001.4.2.167 – volume: 24 start-page: 544 year: 2003 ident: 10.4048/jbc.2012.15.2.172_ref26 publication-title: Eur J Gynaecol Oncol – volume: 41 start-page: 431 year: 2010 ident: 10.4048/jbc.2012.15.2.172_ref10 publication-title: Hum Pathol doi: 10.1016/j.humpath.2009.09.001 – volume: 66 start-page: 965 year: 2011 ident: 10.4048/jbc.2012.15.2.172_ref9 publication-title: Clinics (Sao Paulo) doi: 10.1590/S1807-59322011000600008 – volume: 36 start-page: 1625 year: 1995 ident: 10.4048/jbc.2012.15.2.172_ref18 publication-title: J Nucl Med – volume: 136 start-page: 219 year: 2010 ident: 10.4048/jbc.2012.15.2.172_ref1 publication-title: J Cancer Res Clin Oncol doi: 10.1007/s00432-009-0652-y – volume: 123 start-page: 309 year: 1956 ident: 10.4048/jbc.2012.15.2.172_ref3 publication-title: Science doi: 10.1126/science.123.3191.309 – volume: 4 start-page: 891 year: 2004 ident: 10.4048/jbc.2012.15.2.172_ref19 publication-title: Nat Rev Cancer doi: 10.1038/nrc1478 – volume: 131 start-page: 18 year: 2007 ident: 10.4048/jbc.2012.15.2.172_ref13 publication-title: Arch Pathol Lab Med doi: 10.5858/2007-131-18-ASOCCO – volume: 5 start-page: 667 year: 1993 ident: 10.4048/jbc.2012.15.2.172_ref17 publication-title: Cell Signal doi: 10.1016/0898-6568(93)90028-K – volume: 134 start-page: 907 year: 2010 ident: 10.4048/jbc.2012.15.2.172_ref12 publication-title: Arch Pathol Lab Med doi: 10.5858/134.6.907 – volume: 56 start-page: 37 year: 2006 ident: 10.4048/jbc.2012.15.2.172_ref2 publication-title: CA Cancer J Clin doi: 10.3322/canjclin.56.1.37 – volume: 6 start-page: e23205 year: 2011 ident: 10.4048/jbc.2012.15.2.172_ref5 publication-title: PLoS One doi: 10.1371/journal.pone.0023205 – volume: 276 start-page: 9519 year: 2001 ident: 10.4048/jbc.2012.15.2.172_ref6 publication-title: J Biol Chem doi: 10.1074/jbc.M010144200 – volume: 40 start-page: 44 year: 2009 ident: 10.4048/jbc.2012.15.2.172_ref23 publication-title: Sichuan Da Xue Xue Bao Yi Xue Ban – volume: 457 start-page: 53 year: 2010 ident: 10.4048/jbc.2012.15.2.172_ref22 publication-title: Virchows Arch doi: 10.1007/s00428-010-0938-0 – volume: 26 start-page: 1279 year: 2011 ident: 10.4048/jbc.2012.15.2.172_ref25 publication-title: Histol Histopathol – volume: 72 start-page: 2979 year: 1993 ident: 10.4048/jbc.2012.15.2.172_ref14 publication-title: Cancer doi: 10.1002/1097-0142(19931115)72:10<2979::AID-CNCR2820721020>3.0.CO;2-X – volume: 19 start-page: 12 year: 2009 ident: 10.4048/jbc.2012.15.2.172_ref7 publication-title: Semin Cancer Biol doi: 10.1016/j.semcancer.2008.11.009 – volume: 22 start-page: 339 year: 2006 ident: 10.4048/jbc.2012.15.2.172_ref29 publication-title: Kaohsiung J Med Sci doi: 10.1016/S1607-551X(09)70320-1 – volume: 15 start-page: 2895 issue: 6B year: 1995 ident: 10.4048/jbc.2012.15.2.172_ref30 publication-title: Anticancer Res – volume: 56 start-page: 622 year: 1994 ident: 10.4048/jbc.2012.15.2.172_ref15 publication-title: Int J Cancer doi: 10.1002/ijc.2910560503 – volume: 4 start-page: 161 year: 2001 ident: 10.4048/jbc.2012.15.2.172_ref27 publication-title: J Korean Breast Cancer Soc doi: 10.4048/jkbcs.2001.4.2.161 – volume: 153 start-page: 798 year: 1995 ident: 10.4048/jbc.2012.15.2.172_ref16 publication-title: J Urol doi: 10.1016/S0022-5347(01)67725-5 – reference: 19292042 - Sichuan Da Xue Xue Bao Yi Xue Ban. 2009 Jan;40(1):44-7 – reference: 19548375 - Arch Pathol Lab Med. 2007;131(1):18-43 – reference: 21870331 - Histol Histopathol. 2011 Oct;26(10):1279-86 – reference: 21826239 - PLoS One. 2011;6(8):e23205 – reference: 8700847 - Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):1847-52 – reference: 15516961 - Nat Rev Cancer. 2004 Nov;4(11):891-9 – reference: 19655166 - J Cancer Res Clin Oncol. 2010 Feb;136(2):219-25 – reference: 16849102 - Kaohsiung J Med Sci. 2006 Jul;22(7):339-45 – reference: 16449185 - CA Cancer J Clin. 2006 Jan-Feb;56(1):37-47; quiz 50-1 – reference: 8669885 - Anticancer Res. 1995 Nov-Dec;15(6B):2895-8 – reference: 14517300 - Mol Cell Biol. 2003 Oct;23(20):7315-28 – reference: 12417042 - Jpn J Cancer Res. 2002 Oct;93(10):1123-8 – reference: 19114105 - Semin Cancer Biol. 2009 Feb;19(1):12-6 – reference: 8130071 - Cell Signal. 1993 Nov;5(6):667-75 – reference: 8221565 - Cancer. 1993 Nov 15;72(10):2979-85 – reference: 11166147 - Eur J Cancer. 2001 Jan;37(2):204-9 – reference: 8314336 - Int J Cancer. 1994 Mar 1;56(5):622-9 – reference: 11120745 - J Biol Chem. 2001 Mar 23;276(12):9519-25 – reference: 14658600 - Eur J Gynaecol Oncol. 2003;24(6):544-6 – reference: 18992769 - Pharmacol Ther. 2009 Jan;121(1):29-40 – reference: 19954817 - Hum Pathol. 2010 Mar;41(3):431-7 – reference: 7861542 - J Urol. 1995 Mar;153(3 Pt 1):798-801 – reference: 17208433 - Curr Opin Genet Dev. 2007 Feb;17(1):71-7 – reference: 20524868 - Arch Pathol Lab Med. 2010 Jun;134(6):907-22 – reference: 7658223 - J Nucl Med. 1995 Sep;36(9):1625-32 – reference: 21808860 - Clinics (Sao Paulo). 2011;66(6):965-72 – reference: 13298683 - Science. 1956 Feb 24;123(3191):309-14 – reference: 20526721 - Virchows Arch. 2010 Jul;457(1):53-61 |
SSID | ssj0064377 |
Score | 2.0047977 |
Snippet | Glucose uptake and glycolytic metabolism are enhanced in cancer cells, and increased expression of glucose transporter 1 (GLUT1) has also been reported. The... Purpose: Glucose uptake and glycolytic metabolism are enhanced in cancer cells, and increased expression of glucose transporter 1 (GLUT1) has also been... |
SourceID | nrf pubmedcentral proquest pubmed crossref |
SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
StartPage | 172 |
SubjectTerms | Original 일반외과학 |
Title | The Glycolytic Phenotype is Correlated with Aggressiveness and Poor Prognosis in Invasive Ductal Carcinomas |
URI | https://www.ncbi.nlm.nih.gov/pubmed/22807934 https://www.proquest.com/docview/1027042602 https://pubmed.ncbi.nlm.nih.gov/PMC3395740 https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART001671102 |
Volume | 15 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
ispartofPNX | Journal of Breast Cancer, 2012, 15(2), 60, pp.172-180 |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Ra9swEBZdC2Uvo-u6NVsXNNhTIcGWZdl6GiVt1w4y8tBA34QsyW2aIHdOMpZ_vzvZCcsIg2GQMT6dsE5n3emO7wj5LHNTRNxikpS0Pe6YAJ1jBai7FikomGEB1Gf4XdyM-bf79H6PrMtbtRM43-naYT2pcT3r__qx-gIKD_ZrnyPs7FOBWIQx68dpH5oM_sgHsDEJ9MWGfBNUwBBVqLWSgY6DnSyaIOduFlvb1Atfl7ss0L8TKf_Yma6PyKvWpKQXzRp4TfacPyaHwzZo_oZMYSnQr7MViHwFJHT06HyFR690MqcDrM4xA4PTUjySpRcPwQFv_4FUe0tHVVXTUV1hSh70mHh6639qJKGXSwPzRgdYkMhjptEJGV9f3Q1uem2NhZ7hCVv0tAWLy-WGG5aWMi65zqSWeVpEoVZC6qRJcgGXldKysnQ6Sy2GEnnpYu6i5C3Z95V3p4SWRgA3l2nwiDgvoJNNRCFZrjmzsbAdEq2nVJkWgBzrYMwUOCIoBQVSUCgFFacKmox1yPmmy3ODvvEv4k8gJzU1E4WY2Xh_qNS0VuAZ3CouRR4JoFlLUYEeYXBEe1ct58CWZQGuH_i8a6S6GTJABsmEd0i2Je8NAY63_cZPHgNWd4JxUB69_58P-UBe4nOTkHZG9hf10n0E02dRdMORQTcs6244mfoN0tcB-g |
linkProvider | Scholars Portal |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+Glycolytic+Phenotype+is+Correlated+with+Aggressiveness+and+Poor+Prognosis+in+Invasive+Ductal+Carcinomas&rft.jtitle=Journal+of+breast+cancer&rft.au=Jang%2C+Se+Min&rft.au=Han%2C+Hulin&rft.au=Jang%2C+Ki-Seok&rft.au=Jun%2C+Young+Jin&rft.date=2012-06-01&rft.issn=1738-6756&rft.eissn=2092-9900&rft.volume=15&rft.issue=2&rft.spage=172&rft_id=info:doi/10.4048%2Fjbc.2012.15.2.172&rft.externalDBID=n%2Fa&rft.externalDocID=10_4048_jbc_2012_15_2_172 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1738-6756&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1738-6756&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1738-6756&client=summon |